Verinnogen Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Accelerator/Inc
- Latest Deal Amount
-
$677K
- Investors
-
7
Verinnogen General Information
Description
Developer of a hand-held device designed to profile three-dimensional surfaces for pre-clinical cancer research. The company offers tools that improve accuracy and reduce operator error, enabling researchers to achieve more efficient translation of cancer therapies for clinical evaluation.
Contact Information
Website
www.verinnogen.comCorporate Office
- Unit 9 Quy Court
- Cambridge CB25 9AU
- England, United Kingdom
Corporate Office
- Unit 9 Quy Court
- Cambridge CB25 9AU
- England, United Kingdom
Verinnogen Timeline
Verinnogen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Accelerator/Incubator | 11-May-2026 | $677K | Completed | Pre-Clinical Trials | ||
| 3. Later Stage VC | 30-Mar-2026 | Completed | Pre-Clinical Trials | |||
| 2. Later Stage VC | 22-Dec-2025 | $1.13M | $1.65M | Completed | Pre-Clinical Trials | |
| 1. Accelerator/Incubator | 01-Feb-2023 | $520K | $520K | Completed | Pre-Clinical Trials |
Verinnogen Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary A | ||||||||
| Ordinary A | ||||||||
| Ordinary A | 469,741 | $0.000133 | $1.2 | $1.2 | 1x | $1.2 | 21.54% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Verinnogen Patents
Verinnogen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4412519-A1 | Surface profiler | Active | 08-Oct-2021 | ||
| EP-4412519-B1 | Surface profiler | Active | 08-Oct-2021 | ||
| EP-4412519-C0 | Surface profiler | Active | 08-Oct-2021 | ||
| ES-3064067-T3 | Surface profiler | Active | 08-Oct-2021 | ||
| GB-202114406-D0 | Surface profiler | Pending | 08-Oct-2021 | A61B5/1072 |
Verinnogen Signals
Verinnogen Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Centre for Process Innovation | Corporate Venture Capital | Minority | ||
| EverQuest Capital Partners | PE/Buyout | Minority | ||
| Cambridge Angels | Angel Group | Minority | ||
| Cambridge Enterprise Ventures | Venture Capital | Minority | ||
| Cancer Research Technology | Venture Capital | Minority |
Verinnogen FAQs
-
When was Verinnogen founded?
Verinnogen was founded in 2019.
-
Where is Verinnogen headquartered?
Verinnogen is headquartered in Cambridge, United Kingdom.
-
What is the size of Verinnogen?
Verinnogen has 8 total employees.
-
What industry is Verinnogen in?
Verinnogen’s primary industry is Discovery Tools (Healthcare).
-
Is Verinnogen a private or public company?
Verinnogen is a Private company.
-
What is Verinnogen’s current revenue?
The current revenue for Verinnogen is .
-
How much funding has Verinnogen raised over time?
Verinnogen has raised $3M.
-
Who are Verinnogen’s investors?
Centre for Process Innovation, EverQuest Capital Partners, Cambridge Angels, Cambridge Enterprise Ventures, and Cancer Research Technology are 5 of 7 investors who have invested in Verinnogen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process